ALVINE METOHO-EKE: Open Payments
NPI 1306461934 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,003 in 43 payments from 11 companies in 2025. Trend: 2023 $301 · 2024 $250 · 2025 $1,003
Food & beverage: $1,003
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 12 | $294 |
| Neurocrine BioSciences, Inc. | 5 | $151 |
| Vanda Pharmaceuticals Inc. | 5 | $132 |
| ABBVIE INC. | 6 | $109 |
| Otsuka America Pharmaceutical, Inc. | 6 | $105 |
| Lundbeck LLC | 2 | $59 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| Alkermes, Inc. | 1 | $23 |
Products named: COBENFY, INGREZZA, FANAPT, OPDIVO, VRAYLAR, ABILIFY MAINTENA, ABILIFY ASIMTUFII, UZEDY.
Industry payments across TX — which companies pay providers there.
